Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics


Iterum Therapeutics plc - Ordinary Share (ITRM)

Today's Latest Price: $1.41 USD

0.03 (2.18%)

Updated Jan 28 11:15am

Add ITRM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 241 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ITRM Stock Summary

  • Iterum Therapeutics plc's stock had its IPO on May 25, 2018, making it an older stock than only 4.47% of US equities in our set.
  • ITRM's price/sales ratio is 1,370.36; that's higher than the P/S ratio of 99.56% of US stocks.
  • Revenue growth over the past 12 months for Iterum Therapeutics plc comes in at -95.74%, a number that bests just 0.64% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ITRM, based on their financial statements, market capitalization, and price volatility, are SCYX, CBMG, TOCA, INO, and ITCI.
  • ITRM's SEC filings can be seen here. And to visit Iterum Therapeutics plc's official web site, go to www.iterumtx.com.

ITRM Stock Price Chart Interactive Chart >

Price chart for ITRM

ITRM Price/Volume Stats

Current price $1.41 52-week high $6.02
Prev. close $1.38 52-week low $0.45
Day low $1.38 Volume 5,025,338
Day high $1.49 Avg. volume 15,691,596
50-day MA $1.01 Dividend yield N/A
200-day MA $1.37 Market Cap 69.21M

Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.


ITRM Latest News Stream


Event/Time News Detail
Loading, please wait...

ITRM Latest Social Stream


Loading social stream, please wait...

View Full ITRM Social Stream

Latest ITRM News From Around the Web

Below are the latest news stories about Iterum Therapeutics plc that investors may wish to consider to help them evaluate ITRM as an investment opportunity.

Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

-- If approved, First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years -- -- PDUFA goal date of July 25, 2021 -- DUBLIN, Ireland and CHICAGO, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a quinolone non-susceptible pathogen. The FDA has designated this application a...

Yahoo | January 25, 2021

Iterum Therapeutics to Participate in H.C. Wainwright BioConnect Virtual Conference

DUBLIN, Ireland and CHICAGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical…

GlobeNewswire | January 6, 2021

Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors

\--Dr. Dunne resigns as Chief Scientific Officer--\-- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities\--DUBLIN, Ireland and CHICAGO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that Dr. Michael Dunne has resigned from his role as Chief Scientific Officer of the Company, effective December 21, 2020. Dr. Dunne has agreed to be a strategic advisor to the Company actively working as a consultant throughout the regulatory review and potential approval of the ...

Yahoo | December 23, 2020

Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Trading on Nasdaq Capital Market is expected to begin on December 23, 2020DUBLIN, Ireland and CHICAGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that on December 18, 2020, the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) approved the Company's request to transfer its listing to The Nasdaq Capital Market from The Nasdaq Global Market. The transfer is expected to take effect at the opening of business on Wednesday, December 23, 2020. The Company's shares will continue to trade under the symbol “IT...

Yahoo | December 21, 2020

Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority

Bilayer tablet patent application could provide U.S. patent coverage for Iterum’s commercial formulation through 2039, if grantedDUBLIN, Ireland and CHICAGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the filing of a U.S. national phase patent application directed to the composition of the bilayer tablet of sulopenem etzadroxil and probenecid and its related uses with the U.S. Patent and Trademark Office (“USPTO”). “If approved, this U.S. patent application related to the bilayer tablet, which includes both sulopenem etzadrox...

Yahoo | December 7, 2020

Read More 'ITRM' Stories Here

ITRM Price Returns

1-mo 46.60%
3-mo 197.47%
6-mo 35.58%
1-year -46.99%
3-year N/A
5-year N/A
YTD 42.57%
2020 -78.02%
2019 -10.18%
2018 N/A
2017 N/A
2016 N/A

Continue Researching ITRM

Want to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:

Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7208 seconds.